Senti Biosciences Holdings, Inc. 10-K

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Market Information Our common stock is currently listed on The Nasdaq Capital Market under the symbol “SNTI”, and was previously traded under the same symbol on The Nasdaq Global Market. Prior to the consummation of the Merger, our common stock was listed on The Nasdaq Global Market under the symbol “DYNS.” Holders As of March 18, 2025, there were 69 holders of record of our common stock. The number of holders of record does not include for example a substantially greater number of “street name” holders or beneficial holders whose Senti Common Shares are held of record by banks, brokers and other financial institutions. Dividend Policy We have not paid any cash dividends to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition. The payment of any cash dividends will be within the discretion of our Board of Directors at such time. Our ability to declare dividends may also be limited by restrictive covenants pursuant to any future debt financing agreements. Securities Authorized for Issuance Under Equity Compensation Plans The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 11 - Executive Compensation - Equity Compensation Plan Information of Part III of this Annual Report. Recent Sales of Unregistered Securities Pursuant to Chardan’s committed equity facility, we issued and sold 244,313 shares of our common stock to Chardan at a weighted average price of $7.17 per share during the year ended December 31, 2024. We used the net proceeds from these sales for general corporate purposes. In Chardan’s committed equity facility, Chardan represented to us, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act). The shares of common stock referred to in this Annual Report on Form 10-K were issued and sold by us to Chardan in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. On March 17, 2025, the Company provided notice to Chardan that it was terminating the A&R Purchase Agreement. Except as detailed above and in our Current Reports on Form 8-K filed on December 2, 2024 and January 6, 2025, we did not have any sales of unregistered securities during the year ended December 31, 2024. Item 6. [RESERVED]